IBIO
Price
$1.60
Change
+$0.05 (+3.23%)
Updated
Jun 17 closing price
Capitalization
79.49M
103 days until earnings call
Intraday BUY SELL Signals
WVE
Price
$5.95
Change
+$0.21 (+3.66%)
Updated
Jun 17 closing price
Capitalization
1.15B
42 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IBIO vs WVE

IBIO vs WVE Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
IBIO vs. WVE commentary
Jun 18, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IBIO is a Hold and WVE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 18, 2026
Stock price -- (IBIO: $1.60 vs. WVE: $5.96)
Brand notoriety: IBIO and WVE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IBIO: 185% vs. WVE: 131%
Market capitalization -- IBIO: $79.49M vs. WVE: $1.15B
IBIO [@Biotechnology] is valued at $79.49M. WVE’s [@Biotechnology] market capitalization is $1.15B. The market cap for tickers in the [@Biotechnology] industry ranges from $116.49B to $0. The average market capitalization across the [@Biotechnology] industry is $1.95B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IBIO’s FA Score shows that 0 FA rating(s) are green whileWVE’s FA Score has 1 green FA rating(s).

  • IBIO’s FA Score: 0 green, 5 red.
  • WVE’s FA Score: 1 green, 4 red.
According to our system of comparison, WVE is a better buy in the long-term than IBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IBIO’s TA Score shows that 3 TA indicator(s) are bullish while WVE’s TA Score has 6 bullish TA indicator(s).

  • IBIO’s TA Score: 3 bullish, 7 bearish.
  • WVE’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, WVE is a better buy in the short-term than IBIO.

Price Growth

IBIO (@Biotechnology) experienced а -5.88% price change this week, while WVE (@Biotechnology) price change was +5.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.07%. For the same industry, the average monthly price growth was +6.59%, and the average quarterly price growth was +2219.87%.

Reported Earning Dates

IBIO is expected to report earnings on Sep 29, 2026.

WVE is expected to report earnings on Jul 30, 2026.

Industries' Descriptions

@Biotechnology (+4.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
WVE($1.15B) has a higher market cap than IBIO($79.5M). IBIO YTD gains are higher at: -17.098 vs. WVE (-64.941). IBIO has higher annual earnings (EBITDA): -26.4M vs. WVE (-187.88M). WVE has more cash in the bank: 545M vs. IBIO (74.8M). IBIO has less debt than WVE: IBIO (2.33M) vs WVE (15.7M). WVE has higher revenues than IBIO: WVE (71.8M) vs IBIO (300K).
IBIOWVEIBIO / WVE
Capitalization79.5M1.15B7%
EBITDA-26.4M-187.88M14%
Gain YTD-17.098-64.94126%
P/E Ratio0.65N/A-
Revenue300K71.8M0%
Total Cash74.8M545M14%
Total Debt2.33M15.7M15%
FUNDAMENTALS RATINGS
IBIO vs WVE: Fundamental Ratings
IBIO
WVE
OUTLOOK RATING
1..100
6316
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
25
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5288
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

WVE's Valuation (25) in the Biotechnology industry is in the same range as IBIO (56). This means that WVE’s stock grew similarly to IBIO’s over the last 12 months.

WVE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as IBIO (100). This means that WVE’s stock grew similarly to IBIO’s over the last 12 months.

WVE's SMR Rating (100) in the Biotechnology industry is in the same range as IBIO (100). This means that WVE’s stock grew similarly to IBIO’s over the last 12 months.

IBIO's Price Growth Rating (52) in the Biotechnology industry is somewhat better than the same rating for WVE (88). This means that IBIO’s stock grew somewhat faster than WVE’s over the last 12 months.

IBIO's P/E Growth Rating (98) in the Biotechnology industry is in the same range as WVE (100). This means that IBIO’s stock grew similarly to WVE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IBIOWVE
RSI
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
MACD
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 14 days ago
80%
Bullish Trend 3 days ago
76%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 10 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
IBIO
Daily Signal:
Gain/Loss:
WVE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MUETX41.95N/A
N/A
MFS Blended Research Core Equity R3
RLISX25.76N/A
N/A
Russell Inv Equity Income S
AREWX28.88N/A
N/A
American Century Real Estate R
CFNEX101.73-1.00
-0.97%
American Funds Fundamental Invs 529E
NBSTX64.80-1.00
-1.52%
Neuberger Quality Equity Tr

WVE and

Correlation & Price change

A.I.dvisor indicates that over the last year, WVE has been loosely correlated with GPCR. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if WVE jumps, then GPCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To WVE
1D Price
Change %
WVE100%
+3.83%
GPCR - WVE
64%
Loosely correlated
+4.87%
KYMR - WVE
53%
Loosely correlated
+2.81%
FRMM - WVE
44%
Loosely correlated
-3.39%
OCUL - WVE
44%
Loosely correlated
+7.83%
IBIO - WVE
44%
Loosely correlated
+3.23%
More